guest ::
| Home > Publications database > Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: a multicenter study. > print |
| Home > Publications database > Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: a multicenter study. > print |
| 001 | 276332 | ||
| 005 | 20240229154959.0 | ||
| 024 | 7 | _ | |a 10.1093/neuonc/noad096 |2 doi |
| 024 | 7 | _ | |a pmid:37246777 |2 pmid |
| 024 | 7 | _ | |a 1522-8517 |2 ISSN |
| 024 | 7 | _ | |a 1523-5866 |2 ISSN |
| 024 | 7 | _ | |a altmetric:149086718 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2023-01062 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Donson, Andrew M |0 0000-0003-1153-6911 |b 0 |
| 245 | _ | _ | |a Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: a multicenter study. |
| 260 | _ | _ | |a Oxford |c 2023 |b Oxford Univ. Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1698233876_28572 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2023 Oct 3;25(10):1854-1867 |
| 520 | _ | _ | |a Ependymoma (EPN) posterior fossa group A (PFA) has the highest rate of recurrence and the worst prognosis of all EPN molecular groups. At relapse, it is typically incurable even with re-resection and re-irradiation. The biology of recurrent PFA remains largely unknown, however, the increasing use of surgery at first recurrence has now provided access to clinical samples to facilitate a better understanding of this.In this large longitudinal international multicenter study, we examined matched samples of primary and recurrent disease from PFA patients to investigate the biology of recurrence.DNA methylome derived copy number variants (CNVs) revealed large scale chromosome gains and losses at recurrence. CNV changes were dominated by chromosome 1q gain and/or 6q loss, both previously identified as high-risk factors in PFA, which were present in 23% at presentation but increased to 61% at 1 st recurrence. Multivariate survival analyses of this cohort showed that cases with 1q gain or 6q loss at 1 st recurrence were significantly more likely to recur again. Predisposition to 1q+/6q- CNV changes at recurrence correlated with hypomethylation of heterochromatin-associated DNA at presentation. Cellular and molecular analyses revealed that 1q+/6q- PFA had significantly higher proportions of proliferative neuroepithelial undifferentiated progenitors and decreased differentiated neoplastic subpopulations.This study provides clinically and preclinically-actionable insights into the biology of PFA recurrence. The hypomethylation predisposition signature in PFA is a potential risk-classifier for trial stratification. We show that the cellular heterogeneity of PFAs evolves largely because of genetic evolution of neoplastic cells. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a chromosomal instability |2 Other |
| 650 | _ | 7 | |a ependymoma |2 Other |
| 650 | _ | 7 | |a prognosis |2 Other |
| 650 | _ | 7 | |a recurrence |2 Other |
| 700 | 1 | _ | |a Bertrand, Kelsey C |0 0000-0001-6382-5411 |b 1 |
| 700 | 1 | _ | |a Riemondy, Kent A |0 0000-0002-2464-7808 |b 2 |
| 700 | 1 | _ | |a Gao, Dexiang |0 0000-0003-3920-7060 |b 3 |
| 700 | 1 | _ | |a Zhuang, Yonghua |0 0000-0002-1822-2395 |b 4 |
| 700 | 1 | _ | |a Sanford, Bridget |0 0000-0002-2173-0198 |b 5 |
| 700 | 1 | _ | |a Norris, Gregory A |0 0000-0002-4131-5282 |b 6 |
| 700 | 1 | _ | |a Chapman, Rebecca J |0 0000-0001-8050-8426 |b 7 |
| 700 | 1 | _ | |a Fu, Rui |b 8 |
| 700 | 1 | _ | |a Willard, Nicholas |0 0000-0003-4912-201X |b 9 |
| 700 | 1 | _ | |a Griesinger, Andrea M |0 0000-0002-2831-1009 |b 10 |
| 700 | 1 | _ | |a de Sousa, Graziella Ribeiro |0 0000-0003-1809-8539 |b 11 |
| 700 | 1 | _ | |a Amani, Vladimir |0 0000-0002-2280-2317 |b 12 |
| 700 | 1 | _ | |a Grimaldo, Enrique |b 13 |
| 700 | 1 | _ | |a Hankinson, Todd C |0 0000-0002-6288-9496 |b 14 |
| 700 | 1 | _ | |a Booker, Ffyona |b 15 |
| 700 | 1 | _ | |a Sill, Martin |0 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b |b 16 |u dkfz |
| 700 | 1 | _ | |a Grundy, Richard G |0 0000-0002-2585-2539 |b 17 |
| 700 | 1 | _ | |a Pajtler, Kristian |0 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d |b 18 |u dkfz |
| 700 | 1 | _ | |a Ellison, David W |b 19 |
| 700 | 1 | _ | |a Foreman, Nicholas K |0 0000-0003-4848-4801 |b 20 |
| 700 | 1 | _ | |a Ritzmann, Timothy A |0 0000-0002-4438-6588 |b 21 |
| 773 | _ | _ | |a 10.1093/neuonc/noad096 |g p. noad096 |0 PERI:(DE-600)2094060-9 |n 10 |p 1854-1867 |t Neuro-Oncology |v 25 |y 2023 |x 1522-8517 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:276332 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 16 |6 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 18 |6 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2022-11-08 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2022-11-08 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-10-24 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEURO-ONCOLOGY : 2022 |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-24 |
| 915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b NEURO-ONCOLOGY : 2022 |d 2023-10-24 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|